Medical Cannabis Fundamentals
Expert-defined terms from the Executive Certificate in Medical Cannabis Care and Management course at Greenwich School of Business and Finance. Free to read, free to share, paired with a professional course.
Absorption #
Absorption
Explanation #
The process by which cannabinoids move from the site of administration into the bloodstream. Inhalation leads to rapid absorption within minutes, while oral ingestion may take 30‑90 minutes. Practical application includes selecting the appropriate route for acute pain relief. Challenges involve variability due to gastric emptying, food effects, and individual metabolic differences.
Acute Tolerance #
Acute Tolerance
Explanation #
A short‑term reduction in response after repeated dosing over a few hours or days. For example, patients using vaporized cannabis may notice diminished analgesic effect after several sessions. Clinically, clinicians may advise intermittent dosing schedules. The main challenge is distinguishing acute tolerance from long‑term tolerance, which requires different management strategies.
Adverse Event #
Adverse Event
Explanation #
Any undesirable medical occurrence temporally associated with cannabis use, regardless of causality. Common events include dizziness, dry mouth, and tachycardia. Documentation of adverse events is essential for pharmacovigilance. Challenges include under‑reporting by patients who view symptoms as “normal” or “expected.”
Agonist #
Agonist
Explanation #
A substance that binds to a receptor and activates it, producing a biological response. Δ9‑THC acts as a partial agonist at CB1 receptors, eliciting psychoactive effects. Understanding agonist activity helps clinicians predict therapeutic versus psychoactive outcomes. A challenge is that agonist potency varies among cannabis strains.
Analgesia #
Analgesia
Explanation #
Relief from pain achieved through pharmacologic or non‑pharmacologic means. Cannabis‑derived products provide analgesia via CB1‑mediated central mechanisms and CB2‑mediated peripheral anti‑inflammatory pathways. Practical use includes titrating doses for chronic pain patients. Challenges involve patient variability in response and risk of tolerance.
Anxiolytic #
Anxiolytic
Explanation #
A property that reduces anxiety. Cannabidiol (CBD) exhibits anxiolytic effects without significant CB1 activation, making it suitable for patients with anxiety‑related conditions. Clinicians may start with low CBD‑dominant formulations. Challenges include distinguishing anxiolytic benefit from sedation and accounting for individual sensitivity.
Bioavailability #
Bioavailability
Explanation #
The proportion of an administered dose that reaches systemic circulation unchanged. Oral cannabis products have bioavailability of 10‑20% due to hepatic first‑pass metabolism, whereas inhalation can exceed 30%. Selecting a route with higher bioavailability may improve therapeutic efficiency. Challenges include inter‑patient variability and food‑drug interactions.
Cannabinoid #
Cannabinoid
Explanation #
A chemical compound that interacts with the endocannabinoid system. Over 100 cannabinoids have been identified, with Δ9‑THC and CBD being the most studied. Understanding specific cannabinoid profiles guides formulation selection for targeted indications. Challenges arise from complex mixture effects and limited standardization.
Cannabinoid Receptor #
Cannabinoid Receptor
Explanation #
G‑protein coupled receptors that mediate cannabinoid signaling. CB1 is primarily central nervous system, influencing cognition and pain; CB2 is peripheral, modulating immune response. Clinicians must consider receptor distribution when predicting therapeutic outcomes. Challenges include receptor desensitization with chronic exposure.
CB1 Receptor #
CB1 Receptor
Explanation #
The receptor subtype responsible for most central effects of Δ9‑THC, including euphoria, memory impairment, and appetite stimulation. Antagonism of CB1 can reduce appetite, useful in weight‑loss contexts. Practical application includes using CBD‑rich products to limit CB1 activation. Challenges involve balancing efficacy with potential cognitive side effects.
CB2 Receptor #
CB2 Receptor
Explanation #
Predominantly expressed on immune cells, CB2 activation reduces inflammation and cytokine release. Products with higher CBD or CBG may preferentially engage CB2, offering therapeutic benefit for autoimmune disorders. The challenge is quantifying CB2 engagement in heterogeneous plant extracts.
CBD (Cannabidiol) #
CBD (Cannabidiol)
Explanation #
A major non‑psychoactive cannabinoid that modulates several receptors, including 5‑HT1A and TRPV1, and indirectly influences endocannabinoid tone. FDA‑approved Epidiolex demonstrates seizure control; off‑label uses include anxiety and pain. Practical dosing starts at 5‑10 mg/day, titrated upward. Challenges include drug‑drug interactions via CYP450 inhibition.
Δ9‑THC (Δ9‑Tetrahydrocannabinol) #
Δ9‑THC (Δ9‑Tetrahydrocannabinol)
Explanation #
The primary psychoactive cannabinoid responsible for euphoria, analgesia, and appetite stimulation. Δ9‑THC undergoes hepatic metabolism to 11‑hydroxy‑THC, a potent metabolite. Clinical use often involves low‑dose regimens to minimize side effects. Challenges include variability in potency across strains and risk of acute psychosis in vulnerable patients.
Terpenes #
Terpenes
Explanation #
Aromatic compounds contributing to the scent and potentially modulating cannabinoid activity. Myrcene may enhance permeability, while limonene may have mood‑elevating effects. Practically, clinicians can select strains based on terpene profile to complement therapeutic goals. Challenges involve limited scientific consensus on specific terpene‑cannabinoid synergies.
Endocannabinoid #
Endocannabinoid
Explanation #
Endogenously produced lipids that bind CB1 and CB2 receptors, regulating homeostasis. Anandamide (AEA) and 2‑arachidonoylglycerol (2‑AG) are the most studied. Exogenous cannabinoids can augment or inhibit endocannabinoid signaling. Challenges include measuring endogenous levels in clinical practice.
Endocannabinoid System (ECS) #
Endocannabinoid System (ECS)
Explanation #
A complex network of receptors, endogenous ligands, and metabolic enzymes that maintains physiological balance. Dysregulation of the ECS is implicated in chronic pain, mood disorders, and metabolic disease. Understanding ECS status can guide personalized cannabis therapy. Challenges include lack of routine diagnostic assays for ECS function.
Entourage Effect #
Entourage Effect
Explanation #
The hypothesis that cannabinoids, terpenes, and other phytochemicals work together to produce a therapeutic effect greater than isolated compounds. For instance, a full‑spectrum extract may provide superior analgesia compared with pure THC. Practical implication: Clinicians may prefer full‑spectrum products for multi‑symptom patients. Challenges include variability in product composition and limited regulatory standards.
Epidiolex #
Epidiolex
Explanation #
The first FDA‑approved cannabis‑derived medication, containing purified CBD for treatment of Lennox‑Gastaut and Dravet syndromes. Dosing starts at 2.5 Mg/kg twice daily, titrated to 20 mg/kg. Demonstrates robust seizure reduction. Challenges include high cost, insurance coverage, and potential hepatic enzyme interactions.
FDA (Food and Drug Administration) #
FDA (Food and Drug Administration)
Explanation #
U.S. Agency responsible for evaluating safety and efficacy of medical products, including cannabis‑derived medications. While FDA has approved Epidiolex, it has not approved whole‑plant cannabis products. Clinicians must differentiate between FDA‑regulated drugs and state‑regulated medical cannabis. Challenges involve navigating divergent federal and state regulations.
GPR55 #
GPR55
Explanation #
A G‑protein coupled receptor sometimes referred to as the “fifth cannabinoid receptor.” Certain cannabinoids, such as Δ9‑THCV, act as antagonists, influencing blood pressure and bone metabolism. Practical relevance is emerging, especially in metabolic research. Challenges include limited clinical data and assay availability.
Hyperemesis Syndrome #
Hyperemesis Syndrome
Explanation #
A paradoxical condition characterized by cyclic vomiting in chronic, high‑dose cannabis users. Management includes cessation of cannabis and supportive care. Clinicians should screen for this syndrome when patients present with unexplained vomiting. Challenges involve patient reluctance to discontinue a perceived therapeutic agent.
Indica #
Indica
Explanation #
A botanical classification traditionally associated with shorter, bushier plants and a purported relaxing effect. Indica‑dominant products often have higher CBD or myrcene content, leading to muscle relaxation. Practical selection may benefit patients with insomnia or spasticity. Challenges include the oversimplification of plant taxonomy; chemical profile is more predictive than label.
Sativa #
Sativa
Explanation #
Typically tall, narrow‑leafed plants historically linked to uplifting, cerebral effects. Sativa‑dominant products often contain higher Δ9‑THC and limonene. May be chosen for mood elevation or daytime use. Challenges include variability in cannabinoid ratios and potential for anxiety in susceptible individuals.
Hybrid #
Hybrid
Explanation #
Plants resulting from crossing indica and sativa lineages, producing a spectrum of effects. Hybrid formulations can be tailored to desired THC:CBD ratios. Clinicians can use hybrids to balance analgesia with minimal sedation. Challenges involve inconsistent labeling and consumer misunderstanding of “hybrid” effects.
Pharmacokinetics #
Pharmacokinetics
Explanation #
The study of how the body absorbs, distributes, metabolizes, and eliminates cannabinoids. Key parameters include Cmax, Tmax, half‑life (~1‑2 hours for THC, longer for metabolites). Understanding PK informs dosing intervals and titration strategies. Challenges arise from inter‑individual variability and route‑specific differences.
Pharmacodynamics #
Pharmacodynamics
Explanation #
The relationship between cannabinoid concentrations at the site of action and the resulting therapeutic or adverse effects. THC exhibits partial agonism at CB1, producing dose‑dependent psychoactivity; CBD acts as a negative allosteric modulator. Clinicians must align pharmacodynamic expectations with patient goals. Challenges include polypharmacy interactions altering receptor activity.
Dosing #
Dosing
Explanation #
Determining the appropriate amount of cannabis product to achieve desired effect while minimizing side effects. Start‑low, go‑slow is the standard paradigm: E.G., 2.5 Mg THC for novices, increasing by 2.5‑5 Mg every 3‑7 days. Practical dosing guides are essential for safe prescribing. Challenges include patient self‑titration and lack of standardized dosing units across products.
Titration #
Titration
Explanation #
Gradual adjustment of dose to find the minimal effective amount. For chronic pain, clinicians may begin with 1‑2 mg THC and increase until relief is achieved without intolerable side effects. Titration supports individualized therapy. Challenges involve patient adherence and confusion when multiple product types are used concurrently.
Route of Administration #
Route of Administration
Explanation #
The pathway by which cannabis reaches systemic circulation—smoking, vaporization, oral ingestion, sublingual, topical, rectal, or transdermal. Each route has distinct PK profiles, onset times, and safety considerations. Selection depends on condition, patient preference, and comorbidities. Challenges include balancing rapid onset with pulmonary risk, especially in patients with respiratory disease.
Inhalation #
Inhalation
Explanation #
Delivery of cannabinoids via the lungs, producing rapid onset (minutes) and moderate bioavailability. Vaporizing reduces combustion by‑products compared with smoking, decreasing respiratory irritation. Practical use includes acute breakthrough pain. Challenges involve device cost, patient technique variability, and concerns about long‑term lung health.
Vaporization #
Vaporization
Explanation #
Heating cannabis material below the combustion point (typically 160‑210 °C) to release cannabinoids as aerosol. Allows precise dosing and preserves terpene profile. Clinicians may recommend vaporization for patients needing rapid relief without smoke exposure. Challenges include equipment maintenance, battery reliability, and patient misconceptions about “smoking.”
Oral #
Oral
Explanation #
Administration of cannabis products via swallowing, leading to delayed onset (30‑90 min) and lower bioavailability. Oral formulations include capsules, tablets, and infused foods. Useful for chronic symptom control and nighttime dosing. Challenges include unpredictable absorption due to gastric factors and risk of accidental overconsumption.
Sublingual #
Sublingual
Explanation #
Placement of tincture or spray under the tongue, allowing direct mucosal absorption and faster onset (10‑30 min) than traditional oral routes. Offers dose precision and avoids first‑pass metabolism. Practical for patients with swallowing difficulties. Challenges involve patient compliance and potential irritation of oral mucosa.
Topical #
Topical
Explanation #
Application of cannabis‑infused creams, balms, or patches to skin, providing localized analgesia without systemic psychoactive effects. Often used for arthritis or neuropathic pain. Practical advantage: Minimal systemic exposure. Challenges include limited penetration depth and variability in skin absorption rates.
Rectal #
Rectal
Explanation #
Administration of cannabis via suppository, offering higher bioavailability than oral ingestion and bypassing first‑pass metabolism. May be considered for patients unable to take oral medications. Practical use is rare and typically reserved for severe nausea or refractory pain. Challenges include patient acceptance and limited product availability.
Transdermal #
Transdermal
Explanation #
Delivery of cannabinoids through skin patches for sustained systemic exposure over 12‑24 hours. Provides steady plasma levels, useful for chronic pain management. Practical example: CBD‑rich patch delivering 5 mg/hour. Challenges involve ensuring consistent drug release rates and skin irritation.
Nanotechnology #
Nanotechnology
Explanation #
Use of nano‑emulsions or liposomal carriers to increase solubility and absorption of cannabinoids, especially for oral products. Improves onset time and reduces dose variability. Practical application includes nano‑CBD oral sprays. Challenges include regulatory scrutiny, stability concerns, and higher manufacturing costs.
Decarboxylation #
Decarboxylation
Explanation #
Chemical conversion of acidic cannabinoids (e.G., THCA) to their active neutral forms (e.G., THC) through heat. Essential for producing psychoactive effects in smoked or vaporized material. In edibles, cannabis must be decarboxylated before incorporation. Challenges involve controlling temperature to avoid cannabinoid degradation.
Δ9‑THC Acid (THCA) #
Δ9‑THC Acid (THCA)
Explanation #
The precursor to Δ9‑THC, present in raw cannabis. THCA lacks significant CB1 activity and is considered non‑psychoactive. May possess anti‑inflammatory properties. Practical use includes raw juicing or non‑heated preparations. Challenges involve limited clinical data on THCA’s therapeutic potential.
CBG (Cannabigerol) #
CBG (Cannabigerol)
Explanation #
A non‑psychoactive cannabinoid that serves as a biosynthetic precursor to THC and CBD. CBG exhibits antibacterial, neuroprotective, and anti‑inflammatory effects via CB1 antagonism and α‑2 adrenergic modulation. Emerging research suggests utility in glaucoma and inflammatory bowel disease. Challenges include low natural abundance, requiring specialized cultivation.
CBC (Cannabichromene) #
CBC (Cannabichromene)
Explanation #
A non‑psychoactive cannabinoid thought to contribute to analgesia through interaction with TRPA1 and CB2 receptors. CBC may enhance the entourage effect when combined with THC and CBD. Practical use: Full‑spectrum extracts containing CBC for multi‑symptom relief. Challenges involve limited analytical standards and scarcity in commercial products.
THCV (Tetrahydrocannabivarin) #
THCV (Tetrahydrocannabivarin)
Explanation #
A cannabinoid that acts as a neutral antagonist or partial agonist at CB1, potentially reducing appetite and modulating glucose metabolism. Low‑dose THCV may improve metabolic syndrome markers. Practical application includes selecting THCV‑rich strains for patients with obesity. Challenges include dose‑dependent switch to agonism and lack of standardized dosing.
Synthetic Cannabinoid #
Synthetic Cannabinoid
Explanation #
Laboratory‑created compounds that bind cannabinoid receptors with high potency, often far exceeding natural cannabinoids. While some synthetic cannabinoids (e.G., Dronabinol) are FDA‑approved for nausea, many illicit variants cause severe toxicity. Clinicians must differentiate prescribed synthetic agents from illicit analogues. Challenges include unpredictable pharmacology and legal ramifications.
Schedule I #
Schedule I
Explanation #
U.S. Classification denoting substances with high abuse potential and no accepted medical use, currently applied to raw cannabis at the federal level. Limits research and prescribing capabilities. Practical implication: Clinicians must operate under state‑level medical programs. Challenges involve conflicting state‑federal legal frameworks.
Schedule II #
Schedule II
Explanation #
Federal category for substances with accepted medical use but high abuse potential. Synthetic THC (dronabinol) and nabiximols fall under this schedule. Allows prescribing with stricter monitoring. Challenges include insurance coverage and patient access compared with Schedule III or lower categories.
Schedule III #
Schedule III
Explanation #
Classification for drugs with moderate to low abuse potential and accepted medical use, such as certain synthetic cannabinoids. May permit broader prescribing authority. Challenges include maintaining compliance with DEA registration and state regulations.
Medical Cannabis Card #
Medical Cannabis Card
Explanation #
Documentation issued by a state’s medical cannabis program certifying a patient’s eligibility based on qualifying condition. Allows legal purchase from licensed dispensaries. Practical steps include physician certification, application submission, and renewal. Challenges involve varying card validity periods and cross‑state recognition issues.
Physician Certification #
Physician Certification
Explanation #
The formal recommendation by a licensed physician stating that a patient meets criteria for medical cannabis use. Must include diagnosis, treatment rationale, and dosage guidance. Essential for patient enrollment in state programs. Challenges include physician liability concerns and staying current with evolving regulations.
Nurse Practitioner Role #
Nurse Practitioner Role
Explanation #
Advanced practice nurses may evaluate, certify, and manage patients using medical cannabis, depending on state law. Responsibilities include assessment, monitoring, and counseling on safe use. Practical integration improves access in underserved areas. Challenges involve variable prescriptive authority across jurisdictions.
Patient Education #
Patient Education
Explanation #
Providing patients with information on dosing, route selection, side‑effect management, and legal responsibilities. Effective education reduces misuse and improves therapeutic outcomes. Tools include brochures, digital apps, and counseling sessions. Challenges include health literacy variability and misinformation from non‑medical sources.
Contraindications #
Contraindications
Explanation #
Specific conditions or factors where cannabis use may cause harm, such as uncontrolled psychosis, pregnancy, or severe cardiovascular disease. Clinicians must screen and document contraindications before certification. Practical approach includes thorough medical history and risk‑benefit analysis. Challenges involve limited evidence for some contraindications.
Drug Interactions #
Drug Interactions
Explanation #
Cannabinoids can inhibit or induce cytochrome P450 enzymes, altering plasma levels of concurrent medications (e.G., Warfarin, antiepileptics). Clinicians should review patient medication lists and monitor for therapeutic failures or toxicity. Practical strategies include dose adjustments and frequent labs. Challenges include unpredictable interaction magnitude and patient polypharmacy.
CYP450 Enzymes #
CYP450 Enzymes
Explanation #
A family of hepatic enzymes (e.G., CYP3A4, CYP2C19) responsible for metabolizing many drugs and cannabinoids. CBD is a potent inhibitor of CYP3A4, potentially raising levels of co‑administered drugs. Understanding enzyme pathways guides safe co‑prescribing. Challenges arise from inter‑individual genetic polymorphisms affecting enzyme activity.
Metabolite #
Metabolite
Explanation #
A product of drug metabolism that may retain pharmacologic activity. The primary THC metabolite, 11‑hydroxy‑THC, is more psychoactive than THC itself and contributes to intense effects after oral ingestion. Monitoring metabolite levels can aid in assessing compliance. Challenges include limited commercial testing for metabolites in routine practice.
11‑Hydroxy‑THC #
11‑Hydroxy‑THC
Explanation #
A potent metabolite formed in the liver after oral THC intake, responsible for stronger and longer‑lasting psychoactive effects. Clinicians must consider this when prescribing oral formulations to avoid over‑sedation. Practical implication: Start with lower oral doses than inhaled doses. Challenges involve patient variability in hepatic conversion rates.
Side Effect #
Side Effect
Explanation #
An unintended, often mild, effect of a medication, such as dry mouth, conjunctival injection, or mild dizziness. Distinguishing side effects from therapeutic effects assists in dose optimization. Practical management includes dose reduction or switching routes. Challenges include patient misattribution of side effects to unrelated conditions.
Psychosis Risk #
Psychosis Risk
Explanation #
Elevated incidence of acute psychotic episodes in susceptible individuals after high‑dose or chronic THC exposure. Screening for personal or family history of schizophrenia is essential. Practical approach: Limit THC content (<5 %) for high‑risk patients. Challenges involve balancing symptom relief with mental health safety.
Cognitive Impairment #
Cognitive Impairment
Explanation #
Short‑term reductions in attention, memory, and executive function following cannabis use, especially with high THC doses. Clinicians should advise patients to avoid complex tasks for several hours post‑dose. Practical monitoring includes cognitive testing in research settings. Challenges include patient underestimation of impairment severity.
Driving Impairment #
Driving Impairment
Explanation #
Diminished ability to operate a vehicle safely after cannabis consumption. THC blood concentrations do not correlate linearly with impairment, making legal thresholds controversial. Clinicians must counsel patients on abstaining from driving for at least 4‑6 hours after use. Challenges include state‑specific DUI laws and patient compliance.
Pregnancy #
Pregnancy
Explanation #
Use of cannabis during pregnancy is associated with lower birth weight, preterm birth, and neurodevelopmental concerns. Current guidelines advise complete abstinence. Practical recommendation: Discuss cessation strategies and alternative symptom management. Challenges involve patient reluctance and lack of robust randomized data.
Pediatric Use #
Pediatric Use
Explanation #
Limited to FDA‑approved CBD for specific epilepsy syndromes; off‑label use is generally discouraged due to neurodevelopmental concerns. When indicated, dosing is weight‑based and requires close monitoring of liver enzymes. Challenges include parental consent, dosing accuracy, and long‑term safety data.
Geriatric Considerations #
Geriatric Considerations
Explanation #
Older adults may have altered pharmacokinetics, increased sensitivity to THC, and higher fall risk. Starting doses should be reduced (e.G., 1‑2 Mg THC) and titrated slowly. Practical approach includes comprehensive medication review and fall‑risk assessment. Challenges involve balancing pain control with cognitive safety.
Chronic Pain #
Chronic Pain
Explanation #
Persistent pain lasting >3 months, often neuropathic or inflammatory. Cannabis can serve as an adjunct or opioid‑sparing agent. Clinical protocols recommend starting with low THC:CBD ratios and monitoring pain scores using validated scales. Challenges include insurance coverage, patient expectation management, and risk of tolerance.
Neuropathic Pain #
Neuropathic Pain
Explanation #
Pain arising from nerve damage, often resistant to conventional analgesics. Cannabinoids, particularly THC and CBD, modulate nociceptive pathways via CB2 and TRPV1 receptors. Practical use may involve higher THC content for refractory cases. Challenges include differentiating neuropathic from nociceptive pain and ensuring adequate dosing.
Spasticity #
Spasticity
Explanation #
Involuntary muscle stiffness common in MS and spinal cord injury. THC‑rich extracts have demonstrated reductions in spasm frequency and severity. Practical dosing often employs 2‑3 mg THC up to 10 mg per day, titrated based on effect. Challenges include balancing spasm relief with cognitive side effects.
Nausea #
Nausea
Explanation #
Cannabis, particularly THC, activates CB1 receptors in the dorsal vagal complex to reduce nausea and vomiting. Indicated for chemotherapy‑induced nausea when conventional antiemetics fail. Practical dosing starts at 2.5‑5 Mg THC. Challenges involve distinguishing therapeutic benefit from hyperemesis syndrome in chronic users.
Appetite Stimulation #
Appetite Stimulation
Explanation #
“Munchies” effect mediated by CB1 activation in hypothalamic pathways, beneficial for patients with wasting syndromes (e.G., HIV, cancer). Low‑dose THC (2‑5 mg) often sufficient. Practical use includes timing doses before meals. Challenges include potential for excessive caloric intake and weight gain in non‑cachectic patients.
Glaucoma #
Glaucoma
Explanation #
THC can transiently lower intraocular pressure (IOP) by ~25% for 3‑4 hours. However, frequent dosing is required, making it less practical than standard therapies. Practical recommendation: Consider only when conventional treatments are contraindicated. Challenges involve short duration of effect and systemic side effects.
Multiple Sclerosis (MS) #
Multiple Sclerosis (MS)
Explanation #
Cannabis, especially THC‑rich preparations, can reduce spasticity, pain, and bladder dysfunction in MS patients. Clinical trials support modest improvements in patient‑reported outcomes. Practical dosing often utilizes balanced THC:CBD ratios. Challenges include variability in patient response and regulatory limitations for prescribing.
Epilepsy #
Epilepsy
Explanation #
CBD has demonstrated efficacy in reducing seizure frequency for Lennox‑Gastaut and Dravet syndromes, leading to FDA approval. Off‑label THC may have anticonvulsant properties but also pro‑convulsant potential at high doses. Practical approach: Prioritize CBD, monitor liver enzymes. Challenges include drug interactions with antiepileptics and dosing consistency.
Cancer Pain #
Cancer Pain
Explanation #
Cannabis can provide analgesia, improve appetite, and reduce nausea in oncology patients. Studies suggest THC‑CBD combinations may reduce opioid requirements. Practical integration involves multidisciplinary coordination with oncology teams. Challenges include variable insurance coverage and patient stigma.
Palliative Care #
Palliative Care
Explanation #
Use of cannabis to alleviate refractory symptoms such as pain, dyspnea, and anxiety in end‑of‑life care. Emphasis on low‑dose, rapid‑onset formulations for breakthrough symptoms. Practical protocols include “as‑needed” dosing with clear documentation. Challenges involve legal constraints and caregiver education.
Clinical Trial #
Clinical Trial
Explanation #
Research study designed to evaluate efficacy and safety of cannabis interventions. Must adhere to Good Clinical Practice (GCP) and obtain IND approval for investigational products. Practical steps include protocol development, IRB approval, and patient recruitment. Challenges include regulatory hurdles, funding limitations, and participant blinding.
Randomized Controlled Trial (RCT) #
Randomized Controlled Trial (RCT)
Explanation #
Gold‑standard study design where participants are randomly assigned to intervention or control groups, often double‑blinded. RCTs provide high‑quality evidence for cannabis efficacy. Practical example: A double‑blind RCT comparing THC‑CBD spray vs. Placebo for neuropathic pain. Challenges involve creating indistinguishable placebo due to psychoactive effects.
Observational Study #
Observational Study
Explanation #
Non‑interventional research that monitors outcomes in patients using cannabis in routine care. Provides valuable safety data and usage patterns. Practical use includes registry data collection. Challenges include confounding variables, lack of randomization, and self‑reporting bias.
Placebo Effect #
Placebo Effect
Explanation #
Improvement in symptoms attributable to patient expectations rather than active treatment. Particularly strong in subjective outcomes like pain and anxiety. Effective blinding reduces placebo influence. Practical implication: Include active placebos that mimic mild psychoactive cues. Challenges involve ethical considerations of deception.